title: Estradiol induces discordant angiotensin and blood pressure responses to orthostasis in healthy postmenopausal women.
abstract: Postmenopausal estrogen replacement therapy (ERT) is reported to increase angiotensin II under resting conditions. To determine the implications of this increase for cardiovascular regulation during simulated orthostasis, blood pressure (BP), heart rate (HR), renin, angiotensinogen, angiotensin II, and aldosterone were measured at rest and during lower body negative pressure (LBNP; -10, -20, and -40 mm Hg). We studied 13 normotensive postmenopausal women (54+/-2 [mean+/-SE] years) before and after 1 month of oral estradiol 2 mg daily, and 14 premenopausal women. LBNP activated the renin-angiotensin system acutely in premenopausal but not postmenopausal women. Resting renin and aldosterone were unaffected by estradiol, whereas angiotensinogen (P<0.001) and angiotensin II (P<0.01) increased. Renin, aldosterone, and HR responses to LBNP (which tended to be less in postmenopausal women [P=0.06]) were not affected by estradiol. Importantly, angiotensin II was higher on estradiol during all stages of LBNP, and increased 70% above resting values at the end of this stimulus (P<0.05), yet BP was significantly lower, both at rest (P<0.05) and during LBNP (P<0.01). In summary, in normotensive postmenopausal women, estradiol increases angiotensin II, but not aldosterone, at rest and during orthostatic stress, yet lowers, rather than raises, BP under both conditions. Downregulation of vascular and adrenal responsiveness to angiotensin II may protect healthy women against this activation. Loss of such protection may elevate BP and have adverse implications for women with conditions that impair their capacity to counteract the pathological actions of angiotensin II. This may contribute to higher cardiovascular event rates reported in recent ERT trials.
authors.affiliation: Department of Medicine, University Health Network and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. paula.harvey@uhn.on.ca
authors.forename: Paula J
authors.initials: PJ
authors.lastname: Harvey
authors.forename: Beverley L
authors.initials: BL
authors.lastname: Morris
authors.forename: Judith A
authors.initials: JA
authors.lastname: Miller
authors.forename: John S
authors.initials: JS
authors.lastname: Floras
mesh_terms: D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000097:blood*; D000808:Angiotensinogen / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology*; D016022:Case-Control Studies; D004958:Estradiol / Q000009:adverse effects*; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008150:Lower Body Negative Pressure; D008875:Middle Aged; D017698:Postmenopause; D011187:Posture / Q000502:physiology*; D012083:Renin / Q000097:blood; D012084:Renin-Angiotensin System
chemical_list: D000808:Angiotensinogen; D000804:Angiotensin II; D000450:Aldosterone; D004958:Estradiol; D012083:Renin